Skip to main content

Pliant Therapeutics, Inc.

PLRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001746473

No open-market purchases or sales by Pliant Therapeutics, Inc. insiders were filed in the last 90 days; 86 institutions reported holding it in 13F filings for Q2 2026, worth $54.8M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Pliant Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Pliant Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Pliant Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Iannone RobertDirector–Jul 13, 20261
Borellini FlaviaDirector–Jul 13, 20261
Crowell Gayle ADirector–Jun 12, 20261
Huh HoyoungDirector–Jun 12, 20261
MCCOURT Thomas ADirector–Jun 12, 20261
Curnutte John TDirector–Jun 12, 20261
Cline Darren SDirector–Jun 12, 20261
Krognes Steve E.Director–Jun 12, 20261
Coulie BernardPresident and CEO505,601Apr 17, 20263
Cummings Keith LamontChief Financial Officer297,214Apr 17, 20263
Cheung LilyChief Human Resource Officer44,847Apr 17, 20263
Kuo MinnieChief Operating Officer37,806Apr 17, 20263
Pyott David E IDirector–Jun 9, 20250
Bruhn Suzanne LouiseDirector–Jun 9, 20250
Knobil KatharineDirector–Jun 9, 20250
Lefebvre EricChief Medical Officer240,224Jan 27, 20250
Hull HansChief Business Officer251,708Jan 27, 20250
Ouimette MikeGeneral Counsel & Corp. Sec'y105,544Jan 27, 20250
Shah SmitalDirector–Jun 17, 20240
Tepper Robert I10% Owner1,839,160Dec 1, 20220
Third Rock Ventures III, L.P.10% Owner1,839,160Dec 1, 20220
TRV GP III, LLC10% Owner1,839,160Dec 1, 20220
Third Rock Ventures GP III, L.P.10% Owner1,839,160Dec 1, 20220
Exter NeilDirector–Jun 21, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 22, 2026 (view filing)Jan 202 daysCummings Keith LamontChief Financial OfficerSSale−24.0K$1.28−$30.7K−7.5%297.2K after10b5-1
Jan 22, 2026 (view filing)Jan 202 daysCheung LilyChief Human Resource OfficerSSale−7.53K$1.28−$9.64K−14.4%44.8K after10b5-1
Jan 22, 2026 (view filing)Jan 202 daysCoulie BernardPresident and CEOSSale−89.4K$1.28−$114.4K−15.0%505.6K after10b5-1
Jan 22, 2026 (view filing)Jan 202 daysKuo MinnieChief Operating OfficerSSale−6.92K$1.28−$8.85K−15.5%37.8K after10b5-1
Jan 22, 2025 (view filing)Jan 175 daysCoulie BernardPresident and CEOSSale−52.4K$11.20−$587.1K−10.9%430.5K after10b5-1
Jan 22, 2025 (view filing)Jan 175 daysCummings Keith LamontChief Financial OfficerSSale−20.1K$11.20−$225.7K−7.1%262.6K after10b5-1
Jan 22, 2025 (view filing)Jan 175 daysHull HansChief Business OfficerSSale−15.9K$11.20−$178.5K−7.0%211.6K after10b5-1
Jan 22, 2025 (view filing)Jan 175 daysLefebvre EricChief Medical OfficerSSale−18.5K$11.20−$207.0K−8.7%194.6K after10b5-1
Jan 22, 2025 (view filing)Jan 175 daysCheung LilyChief Human Resource OfficerSSale−3.74K$11.20−$41.9K−13.2%24.6K after10b5-1
Jan 22, 2025 (view filing)Jan 17-225 daysOuimette MikeGeneral Counsel & Corp. Sec'ySSale−23.5K$11.11−$261.1K−25.0%70.5K after2 lots10b5-1
Jul 12, 2024 (view filing)Jul 102 daysLefebvre EricChief Medical OfficerSSale−12.3K$11.56−$142.4K−5.5%213.1K after10b5-1
Jul 12, 2024 (view filing)Jul 102 daysHull HansChief Business OfficerSSale−9.90K$11.56−$114.4K−4.2%227.5K after10b5-1
Jul 12, 2024 (view filing)Jul 102 daysCummings Keith LamontChief Financial OfficerSSale−10.9K$11.56−$126.1K−3.7%282.1K after10b5-1
Jul 12, 2024 (view filing)Jul 102 daysCoulie BernardPresident and CEOSSale−38.7K$11.56−$447.5K−7.4%482.9K after10b5-1
Jul 12, 2024 (view filing)Jul 102 daysOuimette MikeGeneral Counsel & Corp. Sec'ySSale−7.66K$11.56−$88.5K−7.5%94.0K after10b5-1
Jan 19, 2024 (view filing)Jan 172 daysCummings Keith LamontChief Financial OfficerSSale−9.78K$17.23−$168.5K−4.8%194.6K after10b5-1
Jan 19, 2024 (view filing)Jan 172 daysHull HansChief Business OfficerSSale−9.79K$17.23−$168.6K−5.0%185.1K after10b5-1
Jan 19, 2024 (view filing)Jan 172 daysCoulie BernardPresident and CEOSSale−25.7K$17.23−$443.2K−7.5%316.4K after10b5-1
Jan 19, 2024 (view filing)Jan 172 daysLefebvre EricChief Medical OfficerSSale−10.3K$17.23−$177.4K−6.2%156.9K after10b5-1
Jan 19, 2024 (view filing)Jan 172 daysOuimette MikeGeneral Counsel & Corp. Sec'ySSale−5.20K$17.23−$89.5K−8.6%55.2K after10b5-1
Aug 7, 2023 (view filing)Aug 3-44 daysHull HansChief Business OfficerSSale−33.1K$20.01−$662.6K−14.5%194.9K after2 lots10b5-1
Aug 7, 2023 (view filing)Aug 34 daysHull HansChief Business OfficerSSale+1.80K$20.00+$36.0K+0.9%206.1K after10b5-1
Jul 21, 2023 (view filing)Jul 201 dayOuimette MikeGeneral Counsel & Corp. Sec'ySSale−4.75K$17.55−$83.5K−7.3%60.4K after10b5-1
Jul 19, 2023 (view filing)Jul 172 daysOuimette MikeGeneral Counsel & Corp. Sec'ySSale−12.8K$18.01−$230.1K−16.4%65.2K after10b5-1
Jul 19, 2023 (view filing)Jul 172 daysLefebvre EricChief Medical OfficerSSale−22.3K$18.01−$402.0K−11.8%167.2K after10b5-1
Jul 19, 2023 (view filing)Jul 172 daysHull HansChief Business OfficerSSale−17.9K$18.01−$323.0K−7.6%219.2K after10b5-1
Jul 19, 2023 (view filing)Jul 172 daysCummings Keith LamontChief Financial OfficerSSale−19.8K$18.01−$356.1K−8.8%204.0K after10b5-1
Jul 19, 2023 (view filing)Jul 172 daysCoulie BernardPresident and CEOSSale−70.2K$18.01−$1.26M−17.0%342.1K after10b5-1
Apr 3, 2023 (view filing)Mar 30-Apr 34 daysOuimette MikeGeneral Counsel & Corp. Sec'ySSale−7.75K$26.62−$206.3K−13.2%50.8K after3 lots10b5-1
Apr 3, 2023 (view filing)Mar 304 daysLefebvre EricChief Medical OfficerSSale−11.2K$26.52−$298.2K−7.2%145.8K after10b5-1
Apr 3, 2023 (view filing)Mar 304 daysHull HansChief Business OfficerSSale−9.04K$26.52−$239.6K−4.3%202.0K after10b5-1
Apr 3, 2023 (view filing)Mar 304 daysCummings Keith LamontChief Financial OfficerSSale−9.96K$26.52−$264.1K−6.3%148.5K after10b5-1
Apr 3, 2023 (view filing)Mar 304 daysCoulie BernardPresident and CEOSSale−35.3K$26.52−$937.2K−11.4%274.8K after10b5-1
Feb 6, 2023 (view filing)Feb 2-34 daysCoulie BernardPresident and CEOSSale−30.0K$33.92−$1.02M−11.1%240.1K after4 lots
Feb 1, 2023 (view filing)Jan 30-Feb 12 daysCoulie BernardPresident and CEOSSale−45.0K$34.48−$1.55M−15.8%240.1K after6 lots
Jan 27, 2023 (view filing)Jan 26-271 dayCoulie BernardPresident and CEOSSale−30.0K$35.49−$1.06M−11.1%240.1K after3 lots
Jan 27, 2023 (view filing)Jan 26-271 dayCoulie BernardPresident and CEOSSale−25.0K$35.11−$877.7K−5.8%409.3K after3 lots
Jan 25, 2023 (view filing)Jan 23-252 daysCoulie BernardPresident and CEOSSale−45.0K$32.50−$1.46M−32.4%93.8K after5 lots
Jan 25, 2023 (view filing)Jan 232 daysCoulie BernardPresident and CEOSSale−15.0K$35.00−$525.0K−3.3%434.3K after
Jan 25, 2023 (view filing)Jan 232 daysOuimette MikeGeneral Counsel & Corp. Sec'ySSale−20.0K$34.19−$683.8K−77.1%5.95K after
Jan 25, 2023 (view filing)Jan 232 daysLefebvre EricChief Medical OfficerSSale−67.5K$34.48−$2.33M−46.7%76.9K after
Jan 25, 2023 (view filing)Jan 232 daysCummings Keith LamontChief Financial OfficerSSale−30.0K$35.00−$1.05M−26.2%84.4K after
Jan 9, 2023 (view filing)Jan 6-93 daysCoulie BernardPresident and CEOSSale−20.0K$19.07−$381.4K−17.6%93.8K after2 lots
Jan 5, 2023 (view filing)Jan 3-42 daysCoulie BernardPresident and CEOSSale−30.0K$19.20−$575.9K−24.2%93.8K after2 lots
Dec 23, 2022 (view filing)Dec 221 dayOuimette MikeGeneral Counsel & Corp. Sec'ySSale−2.93K$19.38−$56.7K−33.0%5.95K after
Dec 21, 2022 (view filing)Dec 201 dayCummings Keith LamontChief Financial OfficerSSale−9.64K$19.10−$184.2K−10.7%80.4K after
Dec 21, 2022 (view filing)Dec 201 dayCoulie BernardPresident and CEOSSale−34.2K$19.10−$653.4K−26.7%93.8K after
Dec 21, 2022 (view filing)Dec 201 dayLefebvre EricChief Medical OfficerSSale−10.9K$19.10−$207.9K−7.0%144.4K after
Dec 21, 2022 (view filing)Dec 201 dayOuimette MikeGeneral Counsel & Corp. Sec'ySSale−4.72K$19.10−$90.1K−34.7%8.88K after
Dec 21, 2022 (view filing)Dec 201 dayHull HansChief Business OfficerSSale−8.75K$19.10−$167.1K−6.0%138.2K after